Latest

alpha-synuclein

·September 22, 2021·4 min read

Immune Cells in the Brain Share the Work

Microglia immune cells can join together to form networks when needed, a new study reports. However, certain mutations associated with Parkinson's disease can impair this process.

Featured Neurology Neuroscience

·September 8, 2021·2 min read

New Information on the Early Stages of Dementia With Lewy Bodies

New findings reinforce the idea that dementia with Lewy bodies can be pathologically classified as two different and distinct disease types.

Featured Neurology Neuroscience

·June 10, 2021·6 min read

Understanding Gut Inflammation May Hold Clues to Mitigating Parkinson’s Onset

Chronic gut inflammation can trigger the clumping of alpha-synuclein in the walls of the colon, a new study reports. Researchers found chronic inflammation in the gut during early life can exacerbate the clumping of alpha-synuclein in the brains of older mice. The findings add to a growing body of evidence which links gut health to Parkinson's disease.

Featured Neurology Neuroscience

·April 28, 2021·7 min read

New Model May Explain the Mystery of Asymmetry in Parkinson’s Disease

A new model of Parkinson's disease sheds light on the asymmetrical motor symptoms, and other disorders, associated with this disease.

This is a computerized representation of a neuron

Featured Genetics Neurology Neuroscience Open Neuroscience Articles

·February 10, 2021·4 min read

Function Identified of ‘Mystery Protein’ That Kills Brain Cells of People With Parkinson’s

Study sheds new light on the damage alpha-synuclein does to neurons in Parkison's disease patients.

Featured Genetics Neurology Open Neuroscience Articles

·August 23, 2020·4 min read

Unique Protein Structures Could Hold the Key to Parkinson’s Disease

Researchers have discovered a series of misfolded alpha-synuclein protein structures never previously observed. The alpha-synuclein fibers were larger than previously reported and adopted a striking variety of shapes. The work lays the foundation for a detailed analysis of misfolded alpha-synuclein structures and could provide a better understanding of the neurobiology of Parkinson's disease.

Featured Neurology Neuroscience Open Neuroscience Articles

·April 30, 2020·3 min read

Researchers unravel protein mystery of three brain diseases

Researchers have identified two different shapes of alpha-synuclein associated with multiple systems atrophy (MSA) and Lewy body dementia. The structure of the protein is helical in MSA, causing the symptoms to occur more quickly and aggressively. In Lewy body dementia, the protein takes on a cylindrical form.

Featured Neurology Neuroscience Open Neuroscience Articles

·April 20, 2020·4 min read

Further evidence autoimmunity plays a role in Parkinson’s disease

T cells that react to alpha-synuclein are most abundant in the early stages of Parkinson's disease but tend to disappear as the disease progresses. Signs of autoimmunity can appear in Parkinson's patients up to ten years before a diagnosis of the neurodegenerative disease. The detection of T cell response could be an early biomarker for Parkinson's, long before the physical symptoms begin to manifest.

Featured Neurology Neuroscience

·March 13, 2020·5 min read

‘Natural killer’ cells could halt Parkinson’s progression

Natural killer cells may play a critical role in regulating and restraining neuroinflammation and protein clumping associated with Parkinson's disease.

Featured Neurology Neuroscience

·March 11, 2020·5 min read

New target for Parkinson’s therapies identified

Two regions outside of the non-amyloid-beta-component play a critical role in controlling amyloid formation of alpha-synuclein.

Featured Neurology Neuroscience

·February 18, 2020·5 min read

Parkinson’s biomarker may originate in gut

Using mouse models, researchers seeded alpha-synuclein aggregates in gut neurons and discovered the clumps can travel to neurons in the brain.

Featured Neurology Neuroscience Open Neuroscience Articles

·February 16, 2020·4 min read

Cough syrup drug being trialed as Parkinson’s treatment

Ambroxol, a medication approved to treat coughs, may slow the progression of Parkinson's disease. The medication is able to effectively cross the blood-brain barrier and increases levels of GCase in patients' brains. Ambroxol also appears to reduce Parkinson's-related alpha-synuclein levels.

1 2 3 4 … 10

alpha-synuclein

Immune Cells in the Brain Share the Work

New Information on the Early Stages of Dementia With Lewy Bodies

Understanding Gut Inflammation May Hold Clues to Mitigating Parkinson’s Onset

New Model May Explain the Mystery of Asymmetry in Parkinson’s Disease

Function Identified of ‘Mystery Protein’ That Kills Brain Cells of People With Parkinson’s

Unique Protein Structures Could Hold the Key to Parkinson’s Disease

Researchers unravel protein mystery of three brain diseases

Further evidence autoimmunity plays a role in Parkinson’s disease

‘Natural killer’ cells could halt Parkinson’s progression

New target for Parkinson’s therapies identified

Parkinson’s biomarker may originate in gut

Cough syrup drug being trialed as Parkinson’s treatment

Brain’s Internal Disappointment Meter Forces Behavioral Change

Octopuses Can Use Mirrors to Find Food

Why the Brain Doesn’t Need Choices to Generate Intent

Brain Integrates Paper Book Narratives Faster Than Digital

Subscribe